Specialist managers see more shorting activity

James Fiore, primary manager of the Life Science Group Partners sector hedge fund, says the biotech and pharmaceutical-focused fund is presently 'predominantly in biotechnology' as the industry has had 'its worst bear market ever and is over 45% down for the year.'

Fiore says: 'Biotech is dominated in the US by individual investors and they're very skittish at the moment, so finding value in the sector is like shooting fish in a barrel.' He adds that a lot of biotechs are trading at levels below